Marathon Patent Group Announces Third Quarter Financial Results Nasdaq:MARA

(MENAFNEditorial) LOS ANGELES, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Marathon Patent Group, Inc. (NASDAQ:) ("Marathon" or "Company"), today announced its operating results for the three months ended September 30, 2017, as published in its Quarterly Report on Form 10-Q filed today with the Securities and Exchange Commission.

Operating Results for the Three Months Ended September 30, 2017

Total revenue of $163 thousand and $43 thousand for the three months ended September 30, 2017 and September 30, 2016, respectively.

Operating loss was approximately $3.9 million (including non-cash expenses) for the three months ended September 30, 2017 compared to an operating loss of $10.7 million for the three months ended September 30, 2016.

Our GAAP net loss was $(1.06) per basic and diluted share for the three months ended September 30, 2017, with 6,270,299 (all share numbers reflect the one for four reverse split completed on October 30, 2017) weighted average basic and diluted shares outstanding as of September 30, 2017, compared to a GAAP loss of $(1.67) per weighted average basic and diluted share for the three months ended September 30, 2016, with 3,761,786 weighted average basic and diluted shares outstanding as of September 30, 2016, respectively.

On a per share basis, our Non-GAAP net loss was $(0.23) per basic and diluted share for the three months ended September 30, 2017, compared to a Non-GAAP loss of $(0.86) per basic and diluted share for the three months ended September 30, 2017, respectively.

From a strategic perspective, Marathon entered into a definitive purchase agreement to acquire 100% ownership of Global Bit Ventures Inc. ('GBV'), a digital asset technology company that mines cryptocurrencies. GBV has robust infrastructure in place with significant capability for expansion. The closing of the transaction is subject to obtaining requisite approvals. The Company intends to update investors more specifically on the transaction on November 27th, when we will be conducting an investor update conference call.

Conference Call

Marathon will host an investor update conference call to with Chief Executive Officer Doug Croxall and Chief Financial Officer Frank Knuettel II on Monday November 27, 2017 at 4:30 PM ET/1:30 PM PT. To participate in the conference call, investors from the U.S. and Canada should dial (877) 407-0792 ten minutes prior to the scheduled start time. International calls should dial (201) 689-8263.

In addition, the call will be broadcast live over the Internet and can be accessed through the Investor Relations section of the Company's website at . The broadcast will be archived online upon completion of the conference call. A telephonic replay of the conference call will also be available until 11:59 p.m. ET on Monday December 11, 2017 by dialing (844) 512-2921 in the U.S. and Canada and (412) 317-6671 internationally and entering the pin number: 13673885.

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
(Unaudited)

September 30, 2017 December 31, 2016 ASSETS Current assets: Cash $ 122,172 $ 4,998,314 Restricted Cash 3,919,718 - Total cash 4,041,890 4,998,314 Accounts receivable - net of allowance for bad debt of $387,976 and $387,976 for September 30, 2017 and December 31, 2016 123,630 95,069 Note receivable 588,864 225,982 Prepaid expenses and other current assets, net of discounts of $2,659 for September 30, 2017 and $3,724 for December 31, 2016 108,878 202,067 Total current assets 4,863,262 5,521,432 Other assets: Property and equipment, net of accumulated depreciation of $133,224 and $108,407 for September 30, 2017 and December 31, 2016 9,803 28,329 Intangible assets, net of accumulated amortization of $12,813,915 and $11,323,185 for September 30, 2017 and December 31, 2016 7,590,213 12,314,628 Other non current assets, net of discounts of $797 for December 31, 2016 - 201,203 Goodwill 228,401 222,843 Total other assets 7,828,417 12,767,003 Total Assets $ 12,691,679 $ 18,288,435 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 1,954,836 $ 7,217,078 Clouding IP earn out - current portion 32,637 81,930 Revenue share liability 1,225,000 - Warrant liability 2,411,750 - Notes payable, net of discounts of $5,837,363 and $852,404 for September 30, 2017 and December 31, 2016 15,582,156 13,162,007 21,206,379 20,461,015 Long-term liabilities Notes Payable, net of discount of $57,763 for December 31, 2016 - 4,670,502 Clouding IP earn out 681,175 1,400,082 Revenue share liability - 1,000,000 Other long term liability 37,236 43,978 Total long-term liabilities 718,411 7,114,562 Total liabilities 21,924,790 27,575,577 Stockholders' Deficit: Preferred stock Series B, $.0001 par value, 50,000,000 shares authorized: 195,501 issued and outstanding at September 30, 2017 and December 31, 2016 78 78 Common stock, $.0001 par value; 200,000,000 shares authorized; 7,776,016 and 4,638,118 at September 30, 2017 and December 31, 2016 3,111 1,856 Additional paid-in capital 61,833,077 49,877,710 Accumulated other comprehensive income (loss) (450,623 ) (1,060,390 ) Accumulated deficit (70,427,472 ) (57,942,548 ) Total Marathon Patent Group stockholders' equity (9,041,829 ) (9,123,294 ) Noncontrolling interests (191,282 ) (163,848 ) Total deficit (9,233,111 ) (9,287,142 ) Total liabilities and stockholders' deficit $ 12,691,679 $ 18,288,435 The accompanying notes are an integral part to these unaudited consolidated condensed financial statements.

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Unaudited)

For the Three
Months Ended
30-Sep-17 For the Three
Months Ended
30-Sep-16 For the Nine
Months Ended
30-Sep-17 For the Nine
Months Ended
30-Sep-16 Revenues $ 162,713 $ 43,113 $ 609,650 $ 36,452,551 Expenses Cost of revenues 64,836 1,094,378 1,544,322 19,202,118 Amortization of patents and website 457,419 2,030,886 1,803,264 6,018,196 Compensation and related taxes 1,871,946 1,252,571 3,718,034 3,406,841 Consulting fees 133,018 257,420 189,819 903,032 Professional fees 616,125 432,496 1,686,955 1,336,201 General and administrative 213,130 183,771 599,416 612,284 Goodwill impairment - - - 83,000 Patent impairment 723,218 5,531,383 723,218 6,525,273 Total operating expenses 4,079,692 10,782,905 10,265,028 38,086,945 Operating loss from continuing operations (3,916,979 ) (10,739,792 ) (9,655,378 ) (1,634,394 ) Other income (expenses) Other income (expense) 2,252,886 (37,116 ) 3,151,418 (68,647 ) Foreign exchange (loss) (480,240 ) (175,850 ) (463,191 ) (238,073 ) Loss on debt extinguishment (283,237 ) - (283,237 ) - Loss on sale of company (1,519,875 ) - (1,519,875 ) - Change in fair value adjustment of Clouding IP earn out 754,321 1,954,378 768,200 2,122,208 Warrant income (expense) (1,909,879 ) - (1,914,786 ) - Interest income 931 931 2,793 2,793 Interest expense (1,283,223 ) (649,065 ) (2,416,722 ) (2,500,321 ) Total other income (expenses) (2,468,316 ) 1,093,278 (2,675,400 ) (682,040 ) Loss from continuing operations before benefit for income taxes (6,385,295 ) (9,646,514 ) (12,330,778 ) (2,316,434 ) Income tax benefit (expense) (12,191 ) 3,347,909 (29,433 ) 26,974 Net Income (loss) (6,397,486 ) (6,298,605 ) (12,360,211 ) (2,289,460 ) Net income (loss) attributable to Noncontrolling interests (280,000 ) 24,195 (124,714 ) 27,918 Net (loss) attributable to common shareholders $ (6,677,486 ) $ (6,274,410 ) $ (12,484,925 ) $ (2,261,542 ) Income (loss) per common share: Basic $ (1.06 ) $ (1.67 ) $ (2.24 ) $ (0.61 ) Diluted WEIGHTED AVERAGE
COMMON
SHARES OUTSTANDING: Basic 6,270,299 3,761,786 5,564,465 3,736,213 Net loss $ (6,677,486 ) $ (6,274,410 ) $ (12,484,925 ) $ (2,261,542 ) Other comprehensive loss: Unrealized gain on foreign currency translation 482,622 209,159 609,768 306,411 Comprehensive loss (6,194,864 ) (6,065,251 ) (11,875,157 ) (1,955,131 ) Less: comprehensive income (loss) related to non-controlling interest (280,000 ) 24,195 (124,714 ) 27,918 Comprehensive loss attributable to Marathon Patent Group, Inc. $ (6,474,864 ) $ (6,041,056 ) $ (11,999,871 ) $ (1,927,213 ) The accompanying notes are an integral part to these unaudited consolidated condensed financial statements.

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)

For The
Nine Months
Ended
September 30,
2017 For The
Nine Months
Ended
September 30,
2016 Cash flows from operating activities: Net loss $ (12,484,924 ) $ (2,261,542 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation 1,248 3,780 Amortization of patents and website 1,803,264 6,018,196 Deferred tax asset - 531,757 Deferred tax liability - (638,268 ) Loss on sale of companies - - Warrant liability - - Impairment of intangible assets 704,678 6,525,273 Impairment of goodwill - 83,000 Stock based compensation 1,523,187 1,541,615 Stock issued for services - 136,000 Non-cash interest, discount, and financing costs (4,397,381 ) 952,231 Change in fair value of Clouding earnout (768,200 ) (2,122,198 ) Allowance for doubtful accounts - 12,226 Beneficial conversion feature 4,017,729 - Noncontrolling interest (27,435 ) (27,918 ) Other non-cash adjustments 182,024 96,996 Changes in operating assets and liabilities Accounts receivable (28,561 ) 43,763 Bonds posted with courts - 883,695 Prepaid expenses and other assets (269,693 ) (6,652 ) Other non current assets 201,203 - Accounts payable and accrued expenses (5,262,242 ) (557,832 ) Net cash and restricted cash provided by (used in) operating activities (14,805,103 ) 11,214,122 Cash flows from investing activities: Acquisition of patents - (3,552,656 ) Disposal of patents 2,771,757 - Purchase of property, equipment, and other intangible assets (6,291 ) (8,387 ) Net cash provided by (used in) investing activities 2,765,466 (3,561,043 ) Cash flows from financing activities: Payment on note payable in connection with the acquisition of Medtech and Orthophoenix - (2,953,779 ) Payment on Fortress note payable (63,286 ) (5,379,105 ) Payment on 3D Nano license note payable (100,000 ) - Cash received upon issuance of equity (net of issuance costs) 5,158,906 - Issuance of warrants 2,549,084 - Issuance of convertible notes payable 5,500,000 Medtronic note payable 600,000 - Payment of Medtronic note payable (600,000 ) Payments on Seimens notes payable (1,750,000 ) - Payments on notes payable to vendors (125,000 ) - Payments on notes payable, net (103,000 ) (578,804 ) Net cash provided (used in) by financing activities 11,066,704 (8,911,688 ) Effect of exchange rate changes on cash 16,509 (1,592 ) Net decrease in cash (956,424 ) (1,260,201 ) Cash at beginning of period 4,998,314 2,555,151 Cash and restricted cash at end of period $ 4,041,890 $ 1,294,950 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for: Interest expense $ 368,923 $ 1,187,074 Taxes paid $ 29,433 $ 27,682 Cash invested in 3D Nano $ - $ 115,000 SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Revenue share liability incurred in conjunction with note payable $ 225,000 $ - Warrant issued in conjunction with common stock issuance $ 257,957 $ - Note payable issued in conjunction with the acquisition of Munitech patents $ - $ 1,755,635 Note payable issued in conjunction with the acquisition of GE patent - 1,000,000 Note payable issued in conjunction with the acquisition of 3D Nano License - 200,000 The accompanying notes are an integral part to these unaudited consolidated condensed financial statements.

Non-GAAP Reconciliation Non-GAAP Reconciliation For the Quarter
Ended
September 30, 2017 For the Quarter
Ended
September 30, 2016 For the Nine Months
Ended
September 30, 2017 For the Nine Months
Ended
September 30, 2016 Net income (loss) attributable to Common Shareholders $ (6,677,486 ) $ (6,274,410 ) $ (12,484,925 ) $ (2,261,542 ) Non-GAAP Amortization of intangible assets & depreciation 457,719 2,030,886 1,804,512 6,018,196 Equity-based compensation 1,371,480 478,819 1,554,835 1,677,616 Impairment of intangible assets 723,218 5,531,383 723,218 6,608,273 Change in the fair value of the clouding IP liability (754,320 ) (1,954,378 ) (768,199 ) (2,122,208 ) Loss on debt extinguishment 283,237 - 283,237 - Loss on sale of companies 1,519,875 - 1,519,875 - Warrant (Income) Expense, net 1,909,879 - 1,914,786 - Non-cash Other (Income) expense, net (1,323,407 ) - (2,221,939 ) - Non-cash interest expense 1,043,012 288,049 1,489,678 952,231 Deferred tax benefit - (3,347,909 ) - (26,974 ) Other (1,486 ) 12,468 (3,072 ) 28,488 Non-GAAP earnings (loss) $ (1,448,278 ) $ (3,235,092 ) $ (6,187,993 ) $ 10,874,080

The following table sets forth the computation of basic and diluted loss per share on a Non-GAAP basis:

Non-GAAP Reconciliation Non-GAAP Reconciliation For the Quarter
Ended
September 30, 2017 For the Quarter
Ended
September 30, 2016 For the Nine Months
Ended
September 30, 2017 For the Nine Months
Ended
September 30, 2016 Non-GAAP net income (loss) $ (1,448,278 ) $ (3,235,092 ) $ (6,187,993 ) $ 10,874,080 Denominator Weighted average common shares - Basic 6,270,299 3,761,785 5,564,464 3,736,213 Weighted average common shares - Diluted 6,270,299 3,761,785 5,564,464 3,996,067 Non-GAAP earnings (loss) per common share: Non-GAAP earnings (loss) - Basic $ (0.23 ) $ (0.86 ) $ (1.11 ) $ 2.91 Non-GAAP earnings (loss) - Diluted NA NA NA 2.72

About Marathon Patent Group

Marathon is formerly an IP licensing company. On November 2, 2017, the Company announced that it has entered into a definitive purchase agreement to acquire 100% ownership of Global Bit Ventures Inc. ('GBV'), a digital asset technology company that mines cryptocurrencies. GBV has robust infrastructure in place with significant capability for expansion. The closing of the transaction is subject to obtaining requisite approvals. To learn more about Marathon Patent Group, visit . To learn more about Global Bit Ventures, visit

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information

Marathon Patent Group
Jason Assad
678-570-6791

MENAFN2011201700703653ID1096116114

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.